Literature DB >> 22647758

Effect of donor smoking on survival after lung transplantation: a cohort study of a prospective registry.

Robert S Bonser1, Rhiannon Taylor, David Collett, Helen L Thomas, John H Dark, James Neuberger.   

Abstract

BACKGROUND: The risk that a positive smoking history in lung donors could adversely affect survival of transplant recipients causes concern. Conversely, reduction of the donor pool by exclusion of donors with positive smoking histories could compromise survival of patients waiting to receive a transplant. We examined the consequences of donor smoking on post-transplantation survival, and the potential effect of not transplanting lungs from such donors.
METHODS: We analysed the effect of donor smoking on 3 year survival after first adult lung transplantation from brain-dead donors done between July 1, 1999, and Dec 31, 2010, by Cox regression modelling of data from the UK Transplant Registry. We estimated the effect of acceptance of lungs from donors with positive smoking histories on survival and compared it with the effect of remaining on the waiting list for a potential transplant from a donor with a negative smoking history donor, by analysing all waiting-list registrations during the same period with a risk-adjusted sequentially stratified Cox regression model.
FINDINGS: Of 1295 lung transplantations, 510 (39%) used lungs from donors with positive smoking histories. Recipients of such lungs had worse 3 year survival after transplantation than did those who received lungs from donors with negative smoking histories (unadjusted hazard ratio [HR] 1·46, 95% CI 1·20-1·78; adjusted HR 1·36, 1·11-1·67). Independent factors affecting survival were recipient's age, donor-recipient cytomegalovirus matching, donor-recipient height difference, donor's sex, and total ischaemic time. Of 2181 patients registered on the waiting list, 802 (37%) died or were removed from the list without receiving a transplant. Patients receiving lungs from donors with positive smoking histories had a lower unadjusted hazard of death after registration than did those who remained on the waiting list (0·79, 95% CI 0·70-0·91). Patients with septic or fibrotic lung disease registered in 1999-2003 had risk-adjusted hazards of 0·60 (95% CI 0·42-0·87) and 0·39 (0·28-0·55), respectively.
INTERPRETATION: In the UK, an organ selection policy that uses lungs from donors with positive smoking histories improves overall survival of patients registered for lung transplantation, and should be continued. Although lungs from such donors are associated with worse outcomes, the individual probability of survival is greater if they are accepted than if they are declined and the patient chooses to wait for a potential transplant from a donor with a negative smoking history. This situation should be fully explained to and discussed with patients who are accepted for lung transplantation. FUNDING: National Health Service Blood and Transplant.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22647758     DOI: 10.1016/S0140-6736(12)60160-3

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  29 in total

1.  Objective Estimates Improve Risk Stratification for Primary Graft Dysfunction after Lung Transplantation.

Authors:  R J Shah; J M Diamond; E Cantu; J Flesch; J C Lee; D J Lederer; V N Lama; J Orens; A Weinacker; D S Wilkes; D Roe; S Bhorade; K M Wille; L B Ware; S M Palmer; M Crespo; E Demissie; J Sonnet; A Shah; S M Kawut; S L Bellamy; A R Localio; J D Christie
Journal:  Am J Transplant       Date:  2015-04-15       Impact factor: 8.086

2.  Clinical Risk Factors and Prognostic Model for Primary Graft Dysfunction after Lung Transplantation in Patients with Pulmonary Hypertension.

Authors:  Mary K Porteous; James C Lee; David J Lederer; Scott M Palmer; Edward Cantu; Rupal J Shah; Scarlett L Bellamy; Vibha N Lama; Sangeeta M Bhorade; Maria M Crespo; John F McDyer; Keith M Wille; A Russell Localio; Jonathan B Orens; Pali D Shah; Ann B Weinacker; Selim Arcasoy; David S Wilkes; Lorraine B Ware; Jason D Christie; Steven M Kawut; Joshua M Diamond
Journal:  Ann Am Thorac Soc       Date:  2017-10

3.  Devices: Artificial inspiration.

Authors:  Elie Dolgin
Journal:  Nature       Date:  2012-09-27       Impact factor: 49.962

Review 4.  The Future of Lung Transplantation.

Authors:  Katherine A Young; Daniel F Dilling
Journal:  Chest       Date:  2018-08-29       Impact factor: 9.410

5.  Donor smoking is associated with pulmonary edema, inflammation and epithelial dysfunction in ex vivo human donor lungs.

Authors:  L B Ware; J W Lee; N Wickersham; J Nguyen; M A Matthay; C S Calfee
Journal:  Am J Transplant       Date:  2014-08-21       Impact factor: 8.086

Review 6.  Evaluation and Management of the Potential Lung Donor.

Authors:  Andrew Courtwright; Edward Cantu
Journal:  Clin Chest Med       Date:  2017-08-31       Impact factor: 2.878

Review 7.  Postoperative management of lung transplant recipients.

Authors:  Christina C Kao; Amit D Parulekar
Journal:  J Thorac Dis       Date:  2019-09       Impact factor: 2.895

8.  Chest computed tomography imaging improves potential lung donor assessment.

Authors:  Jason M Gauthier; Andrew J Bierhals; Jingxia Liu; Keki R Balsara; Christine Frederiksen; Emily Gremminger; Ramsey R Hachem; Chad A Witt; Elbert P Trulock; Derek E Byers; Roger D Yusen; Patrick R Aguilar; Gary Marklin; Ruben G Nava; Benjamin D Kozower; Michael K Pasque; Bryan F Meyers; G Alexander Patterson; Daniel Kreisel; Varun Puri
Journal:  J Thorac Cardiovasc Surg       Date:  2018-11-24       Impact factor: 5.209

Review 9.  Lung cancer: a rare indication for, but frequent complication after lung transplantation.

Authors:  Dirk Van Raemdonck; Robin Vos; Jonas Yserbyt; Herbert Decaluwe; Paul De Leyn; Geert M Verleden
Journal:  J Thorac Dis       Date:  2016-11       Impact factor: 2.895

10.  Use of lung allografts from brain-dead donors after cardiopulmonary arrest and resuscitation.

Authors:  Anthony W Castleberry; Mathias Worni; Asishana A Osho; Laurie D Snyder; Scott M Palmer; Ricardo Pietrobon; R Duane Davis; Matthew G Hartwig
Journal:  Am J Respir Crit Care Med       Date:  2013-08-15       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.